Vanda Pharmaceuticals

Type: Company
Name: Vanda Pharmaceuticals
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Highest EPS Growth in the Biotechnology Industry Detected for Vanda Pharmaceuticals (VNDA, GILD, SGEN)

(Financial News Network On) Below are the three companies in the Biotechnology industry with the highest year-over-year expected earnings per share (EPS) growth rates. Vanda Pharmaceuticals (NASDAQ:VNDA) is highest with EPS growth of 536.4%. Vanda Pharmaceuticals ... [Published Individual.com - Jul 25 2014]
First reported Jul 21 2014 - Updated Jul 22 2014 - 1 reports

Stock Investors Sell Off Shares of Vanda Pharmaceuticals, Down 2.8%

Vanda Pharmaceuticals (NASDAQ:VNDA) is one of today's biggest movers, down 2.8% to $12.95. The Dow Jones Industrial Average is now trading 0.6% lower to 16,988 and the S&P is trading 0.6% lower to 1,967. ... [Published Individual.com - Jul 21 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on

07/17 18:00 CDT August 7, 2014Conference Call and Webcast to Follow WASHINGTON, July 17, 2014WASHINGTON, July 17, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization ... [Published Finwin - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 2 reports

Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014

Conference Call and Webcast to FollowWASHINGTON , July 17, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous ... [Published Michigan Live - Jul 18 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Healthcare Review: Herbalife, Vanda Pharmaceuticals, NeoGenomics, Ensign Group, BioLife Solutions

U.S. stocks edged lower on Thursday in the wake of fresh U.S. and European Union sanctions on Russia, but some stronger-than-expected earnings reports helped keep declines in check.The U.S. sanctions announced late Wednesday hit some of Russia's biggest ... [Published BioMedReports - Jul 17 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Vanda seeks award in Fanapt licensing dispute

13:24 ET | About: Vanda Pharmaceuticals Inc. (VNDA)In a regulatory filing , Vanda Pharmaceuticals (VNDA -1.2%) discloses that it seeks an award of $539M in its arbitration proceeding with Novartis (NVS -1.1%) over the licensing of Fanapt. Novartis, unsurprisingly, ... [Published Seeking Alpha - Jul 17 2014]
First reported Jul 15 2014 - Updated Jul 16 2014 - 1 reports

Vanda Pharmaceuticals Shares Sinking Lower, Down 5.1%

Written on Tue, 07/15/2014 - 12:29pmBy Amy SchwartzVanda Pharmaceuticals ( NASDAQ:VNDA ), a company whose shares are moving quickly, is trading 5.1% lower to $13.27. The S&P is currently trading 0.3% lower to 1,970 and the Dow Jones Industrial Average ... [Published Comtex SmarTrend - Jul 15 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Shares of Vanda Pharmaceuticals Under Pressure, Down 5.2%

Vanda Pharmaceuticals (NASDAQ:VNDA) is one of today's notable stocks in decline, down 5.2% to $13.25. The Dow is trading fractionally lower to 17,047 and the S&P is currently down 0.2% to 1,972. ... [Published Individual.com - Jul 15 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

3 Small-Cap Biotechs That Institutions Are Loving

If large institutions own a particular stock, especially in large amounts, it can certainly be a component worth looking at.First off, institutional money mangers often have teams of analysts working for them.In addition, institutions have access to all ... [Published Benzinga.com - Jul 07 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

21.5% Return Seen to Date on SmarTrend Vanda Pharmaceuticals Call (VNDA)

Written on Tue, 07/01/2014 - 11:10amBy Amy SchwartzSmarTrend identified an Uptrend for Vanda Pharmaceuticals ( NASDAQ:VNDA ) on June 6th, 2014 at $13.48. In approximately 4 weeks, Vanda Pharmaceuticals has returned 21.48% as of today's recent price of ... [Published Comtex SmarTrend - Jul 01 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Pre-Market Review on Health Care Sector Equities -- Research on Dyax, Repligen, Vanda Pharma, and Ironwood Pharma

/PRNewswire/ --The US markets on Thursday, June 30, 2014 mostly ended on a lower note as the Dow Jones Industrial Average finished at 16,826.60, down 0.15% and the NASDAQ Composite closed at 4,408.18, up 0.23%. The S&P 500 finished the session 0.04% lower ... [Published Nasdaq - Jul 01 2014]
First reported Jun 03 2014 - Updated Jun 03 2014 - 2 reports

European Medicines Agency Accepts HETLIOZ™ (tasimelteon) Marketing Authorization Application for Non-24-Hour Sleep-Wake Disorder in the Totally Blind

WASHINGTON, June 3, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines ... [Published PR Newswire: Health - Jun 03 2014]

Quotes

...6,200,604 ("Sublingual Buccal Effervescent," issued March 13, 2001), 6,974,590 (same title, issued December 13, 2005), and 8,119,158 ( "Effervescent Oral Fentanyl Dosage Form and Methods of Administering Fentanyl" issued February 21, 2012) following a Paragraph IV certification as part of Actavis’ filing of an ANDA to manufacture a generic version of Cephalon's...
...I'm starting to see a lot of talk about the potential head-and-shoulders top that's forming on the Nasdaq 100 Index (NDX)," continued Sapp. "Generally, whenever mainstream media picks up on chart patterns like this, it's a contrarian signal. I would closely monitor the amount of talk there is regarding this formation, as a consensus 'top formation' sentiment among market participants would likely be a signal to take the other side and play technology bullishly."
"The availability of Hetlioz marks a major milestone for totally blind people who have been without an approved, safe and effective treatment for Non-24. We are also excited to bring a broad range of services to patients through HetliozSolutions" said Mihael H Polymeropoulos, Vanda's president and chief executive officer
...Polymeropoulos said the FDA approval of HETLIOZ would not have been accomplished without the heroic efforts of blind patients and their advocates. "We are committed to providing much needed support to patients with Non-24 and facilitating access to this new therapeutic option" Polymeropoulos said

More Content

All (54) | News (27) | Reports (0) | Blogs (22) | Audio/Video (0) | Fact Sheets (0) | Press Releases (5)
sort by: Date | Relevance
Highest EPS Growth in the Biotechnology Industr... [Published Individual.com - Jul 25 2014]
Stock Investors Sell Off Shares of Vanda Pharma... [Published Individual.com - Jul 21 2014]
Vanda Pharmaceuticals to Announce Second Quarte... [Published Finwin - Jul 18 2014]
Vanda Pharmaceuticals to Announce Second Quarte... [Published Michigan Live - Jul 18 2014]
Vanda Pharmaceuticals to Announce Second Quarte... [Published PR Newswire: Health - Jul 18 2014]
Healthcare Review: Herbalife, Vanda Pharmaceuti... [Published BioMedReports - Jul 17 2014]
Vanda seeks award in Fanapt licensing dispute [Published Seeking Alpha - Jul 17 2014]
Get Hedge Fund-Style Returns -- Without The Cra... [Published Yahoo! Finance - Jul 15 2014]
Shares of Vanda Pharmaceuticals Under Pressure,... [Published Individual.com - Jul 15 2014]
Vanda Pharmaceuticals Shares Sinking Lower, Dow... [Published Comtex SmarTrend - Jul 15 2014]
Top 100 Agencies 2014: Harrison and Star [Published Medical Marketing And Media - Jul 09 2014]
3 Small-Cap Biotechs That Institutions Are Loving [Published Benzinga.com - Jul 07 2014]
21.5% Return Seen to Date on SmarTrend Vanda Ph... [Published Comtex SmarTrend - Jul 01 2014]
Pre-Market Review on Health Care Sector Equitie... [Published Nasdaq - Jul 01 2014]
What I Like About The LLY Trade [Published SFO - Jun 26 2014]
New Patents, Clinical Trial Updates, New Agreem... [Published Financial Services - Jun 26 2014]
Court Report - June 2014 #4 [Published JD Supra - Jun 25 2014]
Vanda Pharmaceuticals Makes a Move: Up 5.6% [Published Comtex SmarTrend - Jun 23 2014]
Vanda Pharmaceuticals Crosses Below its 10-day ... [Published Comtex SmarTrend - Jun 20 2014]
Morning Analysis on Top Gainers -- Research on ... [Published Financial Services - Jun 05 2014]
Stocks: New High for the S&P 500; Under Armour ... [Published BARRONS.com Stocks To Watch Today - Jun 04 2014]
Why Vanda Pharmaceuticals (VNDA) Stock Is Surgi... [Published The Street Latest - Jun 04 2014]
EMA accepts Vanda's marketing application for N... [Published PBR - News - Jun 04 2014]
European Medicines Agency Accepts HETLIOZ™ (tas... [Published PR Newswire: Health - Jun 03 2014]
HETLIOZ™ (tasimelteon) Data in Patients with No... [Published PR Newswire: General Business - Jun 03 2014]
Vanda Pharmaceuticals to Present at the Jefferi... [Published PR Newswire: General Business - May 30 2014]
Clinical Trial Updates, Leadership Appointments... [Published PR Newswire: Financial Services - May 15 2014]
Forget Rent: The Cost of These 5 New Drugs Is T... [Published Wall St. Cheat Sheet - May 13 2014]
Biotech Stocks on our Radar -- Research on Immu... [Published Financial Services - May 09 2014]
Biggest Movers: hhgregg, Inc., GT Advanced Tech... [Published Schaeffers Research - May 08 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Vanda Pharmaceuticals to Announce Second Quarte... [Published PR Newswire: Health - Jul 18 2014]
WASHINGTON, July 17, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced ...
Stocks: New High for the S&P 500; Under Armour ... [Published BARRONS.com Stocks To Watch Today - Jun 04 2014]
It was the night before the ECB–and two before US payrolls–and all through the market nothing was stirring, not even…Alright. Some things were stirring, like the shares of Protective Life (PL), Travelers Companies (TRV), Under Armour (UA), Broadcom (BRCM) ...
EMA accepts Vanda's marketing application for N... [Published PBR - News - Jun 04 2014]
The European Medicines Agency (EMA) has accepted to evaluate Vanda Pharmaceuticals' Marketing Authorization Application (MAA) for oral HETLIOZ (tasimelteon) capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). ...
European Medicines Agency Accepts HETLIOZ™ (tas... [Published PR Newswire: Health - Jun 03 2014]
WASHINGTON, June 3, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines ...
HETLIOZ™ (tasimelteon) Data in Patients with No... [Published PR Newswire: General Business - Jun 03 2014]
WASHINGTON, June 2, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) will present additional data from its HETLIOZ™ (tasimelteon) clinical development program at SLEEP 2014, the 28th Annual Meeting of Associated Professional Sleep ...
1 2 3 4 5

Press Releases

sort by: Date | Relevance
New Patents, Clinical Trial Updates, New Agreem... [Published Financial Services - Jun 26 2014]
Morning Analysis on Top Gainers -- Research on ... [Published Financial Services - Jun 05 2014]
Biotech Stocks on our Radar -- Research on Immu... [Published Financial Services - May 09 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published Financial Services - Apr 10 2014]
Breakfast Round-up - 52-Weeks High Reset: NextE... [Published Financial Services - Mar 18 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.